Cite
HARVARD Citation
Weekes, C. et al. (2018). Tivantinib for advanced hepatocellular carcinoma: is MET still a viable target?. Lancet oncology. 19 (5), pp. 591-592. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Weekes, C. et al. (2018). Tivantinib for advanced hepatocellular carcinoma: is MET still a viable target?. Lancet oncology. 19 (5), pp. 591-592. [Online].